80 results on '"GALIANO S."'
Search Results
2. Two finite-difference schemes that preserve the dissipation of energy in a system of modified wave equations
3. Assessing uncertainties in the building of ensemble RCMs over Spain based on dry spell lengths probability density functions
4. Novel mutation in the PTCH1 gene in a patient with Gorlin syndrome with prominent clinical features
5. Programmed cell death in the development of the vertebrate inner ear
6. Malignant Blue Nevus: Report of a New Case: P-167
7. Malignant Melanoma of the Nipple Areola Complex: A Case Report: P-176
8. Innovative instrumentation for HTRB tests on semiconductor power devices.
9. 1273 – Addictive behaviour in an acute mental health unit (granada, southern spain)
10. Building hazard maps of extreme daily rainy events from PDF ensemble, via REA method, on Senegal River Basin.
11. Building hazard maps of extreme daily rainy events from PDF ensemble, via REA method, on Senegal River Basin.
12. Assessing the impact of climate variability and climate change on runoff in West Africa: the case of Senegal and Nakambe River basins.
13. Positivity-preserving methods for a linearised Fisher-KPP equation with consistency properties in the energy domain.
14. G6PD Napoli and Ferrara II: Two New Glucose-6-Phosphate Dehydrogenase Variants having Similar Characteristics but Different Intracellular Lability and Specific Activity.
15. Favism: Erythrocyte Metabolism during Haemolysis and Reticulocytosis.
16. 2-deoxy-glucose-6-phosphate utilization in the study of glucose-6-phosphate dehydrogenase mosaicism
17. Pharmacologic testing of the reversibility of an increased pulmonary vascular resistance (PVR) with prostaglandin E1 (PGE1) before heart transplantation (HTX): final results of the multicenter prophet study
18. The function of catalase-bound NADPH.
19. ETIOLOGICAL ASPECTS OF FAVISM
20. Towards 2030: ministerial agreements on information systems and digital transformation for resilient health systems.
21. From national and regional commitments to global impact: artificial intelligence for equitable public health at the G20.
22. G20's commitment to telehealth for reducing global health disparities: from a global commitment to regional actions.
23. Observed isavuconazole exposure: 5-year experience of azole TDM from a Spanish reference laboratory.
24. Monitoring System of the Mar Menor Coastal Lagoon (Spain) and Its Watershed Basin Using the Integration of Massive Heterogeneous Data.
25. Primary follicular mucinosis in childhood.
26. Alsinol, an arylamino alcohol derivative active against Plasmodium, Babesia, Trypanosoma, and Leishmania: past and new outcomes.
27. Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species.
28. Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies.
29. Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery.
30. ImmunoPEGliposomes for the targeted delivery of novel lipophilic drugs to red blood cells in a falciparum malaria murine model.
31. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
32. New hydrazine and hydrazide quinoxaline 1,4-di-N-oxide derivatives: In silico ADMET, antiplasmodial and antileishmanial activity.
33. Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration.
34. Synthesis, biological evaluation and structure-activity relationships of new quinoxaline derivatives as anti-Plasmodium falciparum agents.
35. Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
36. New amide derivatives of quinoxaline 1,4-di-N-oxide with leishmanicidal and antiplasmodial activities.
37. Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxamido) quinoxaline 1,4-dioxide derivatives.
38. New quinoxaline derivatives as potential MT₁ and MT₂ receptor ligands.
39. Novel sulfonylurea derivatives as H3 receptor antagonists. Preliminary SAR studies.
40. Elimination of rubella and congenital rubella syndrome in the Americas.
41. Guidelines for the documentation and verification of measles, rubella, and congenital rubella syndrome elimination in the region of the Americas.
42. Rubella and congenital rubella syndrome elimination: lessons learned for the future. Preface.
43. New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities.
44. New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents.
45. Aryl piperazine and pyrrolidine as antimalarial agents. Synthesis and investigation of structure-activity relationships.
46. Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action.
47. Building a MCHR1 homology model provides insight into the receptor-antagonist contacts that are important for the development of new anti-obesity agents.
48. New 1-aryl-3-substituted propanol derivatives as antimalarial agents.
49. Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity.
50. New amide derivatives as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.